Paracrine and endocrine effects of adipose tissue on cancer development and progression

Endocrine Reviews

Volumn 32, Issue 4, 2011, Pages 550-570

  Park, Jiyoung ^a   Euhus, David M ^a,b   Scherer, Philipp E ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOCYTOKINE; ADIPONECTIN; ANANDAMIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; AROMATASE INHIBITOR; CILOSTAZOL; COLONY STIMULATING FACTOR; INTERLEUKIN 6; IRBESARTAN; KR 62776; LEPTIN; LOSARTAN; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; RWJ 348260; SEX HORMONE; SOMATOMEDIN; TELMISARTAN; TROGLITAZONE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; BODY MASS; CANCER CELL; CANCER GROWTH; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CELL DIFFERENTIATION; DRUG MECHANISM; ENDOCRINE CELL; ENDOCRINE FUNCTION; FIBROSIS; HUMAN; HYPOXIA; IMMUNOCOMPETENT CELL; INFLAMMATION; METABOLIC REGULATION; NEOPLASM; NONHUMAN; OBESITY; OBESITY RELATED CANCER; PARACRINE SIGNALING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; TUMOR MICROENVIRONMENT; WEIGHT GAIN;

ADIPOCYTES; ADIPOSE TISSUE; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; OBESITY; PARACRINE COMMUNICATION;

EID: 80052178280     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.2010-0030     Document Type: Review

References (199)

1. Rajala MW, Scherer PE 2003 Minireview: the adipocyte-at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 144:3765-3773.
2. Lionetti L, Mollica MP, Lombardi A, Cavaliere G, Gifuni G, Barletta A 2009 From chronic overnutrition to insulin resistance: the role of fat-storing capacity and inflammation. Nutr Metab Cardiovasc Dis 19:146-152.
3. Guilherme A, Virbasius JV, Puri V, Czech MP 2008 Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 9:367-377.
4. Blüher M 2009 Adipose tissue dysfunction in obesity. Exp Clin Endocrinol Diabetes 117:241-250.
5. Calle EE, Kaaks R 2004 Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4:579-591.
6. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D 2007 Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 335:1134.
7. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M 2008 Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371:569-578.
8. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ 2003 Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625-1638.
9. Qian BZ, Pollard JW 2010 Macrophage diversity enhances tumor progression and metastasis. Cell 141:39-51.
10. Iyengar P, Combs TP, Shah SJ, Gouon-Evans V, Pollard JW, Albanese C, Flanagan L, Tenniswood MP, Guha C, Lisanti MP, Pestell RG, Scherer PE 2003 Adipocytesecreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilization. Oncogene 22:6408-6423.
11. Iyengar P, Espina V, Williams TW, Lin Y, Berry D, Jelicks LA, Lee H, Temple K, Graves R, Pollard J, Chopra N, Russell RG, Sasisekharan R, Trock BJ, Lippman M, Calvert VS, Petricoin 3rd EF, Liotta L, Dadachova E, Pestell RG, Lisanti MP, Bonaldo P, Scherer PE 2005 Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J Clin Invest 115:1163-1176.
12. Nomura DK, Long JZ, Niessen S, Hoover HS, Ng SW, Cravatt BF 2010 Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 140: 49-61.
13. Hanahan D, Weinberg RA 2000 The hallmarks of cancer. Cell 100:57-70.
14. Hanahan D, Weinberg RA 2011 Hallmarks of cancer: the next generation. Cell 144:646-674.
15. Castellot Jr JJ, Karnovsky MJ, Spiegelman BM 1982 Differentiation-dependent stimulation of neovascularization and endothelial cell chemotaxis by 3T3 adipocytes. Proc Natl Acad Sci USA 79:5597-5601.
16. Vander Heiden MG, Cantley LC, Thompson CB 2009 Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029-1033.
17. Hsu PP, Sabatini DM 2008 Cancer cell metabolism: Warburg and beyond. Cell 134:703-707.
18. Thomson CA, Thompson PA 2009 Dietary patterns, risk and prognosis of breast cancer. Future Oncol 5:1257-1269.
19. Spalding KL, Arner E, Westermark PO, Bernard S, Buchholz BA, Bergmann O, Blomqvist L, Hoffstedt J, Näslund E, Britton T, Concha H, Hassan M, Rydén M, Frisén J, Arner P 2008 Dynamics of fat cell turnover in humans. Nature 453:783-787.
20. Rosen ED, MacDougald OA 2006 Adipocyte differentiation from the inside out. Nat Rev Mol Cell Biol 7:885-896.
21. Kai S, Kusminski CM, Scherer PE 2011 Adipose tissue remodeling and obesity. J Clin Invest 10.1172/JCI45887.
22. Wellen KE, Hotamisligil GS 2005 Inflammation, stress, and diabetes. J Clin Invest 115:1111-1119.
23. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, Tuncman G, Gürgün C, Glimcher LH, Hotamisligil GS 2004 Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306:457-461.
24. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, MakishimaM, MatsudaM, Shimomura I 2004 Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114:1752-1761.
25. Ibrahim MM 2010 Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev 11: 11-18.
26. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H, Karin M 2010 Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140: 197-208.
27. Motrescu ER, Rio MC 2008 Cancer cells, adipocytes and matrix metalloproteinase 11: a vicious tumor progression cycle. Biol Chem 389:1037-1041.
28. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA 2005 Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121: 335-348.
29. Oft M, Heider KH, Beug H 1998 TGFγ signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol 8:1243-1252.
30. Thiery JP, Sleeman JP 2006 Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7:131-142.
31. Peinado H, Olmeda D, CanoA 2007 Snail, Zeb andbHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 7:415-428.
32. Pérez-Mancera PA, Bermejo-Rodríguez C, González-Herrero I, Herranz M, Flores T, Jiménez R, Sánchez-García I 2007 Adipose tissue mass is modulated by SLUG (SNAI2). Hum Mol Genet 16:2972-2986.
33. Zamani N, BrownCW 20 December 2010 Emerging roles for the transforming growth factor-β superfamily in regulating adiposity and energy expenditure. Endocr Rev 10.1210/er.2010-0018.
34. Pettersson AT, Mejhert N, Jernås M, Carlsson LM, Dahlman I, Laurencikiene J, Arner P, RydénM 2011 Twist1 in human white adipose tissue and obesity. J Clin Endocrinol Metab 96:133-141.
35. Battula VL, Evans KW, Hollier BG, Shi Y, Marini FC, Ayyanan A, Wang RY, Brisken C, Guerra R, Andreeff M, Mani SA 2010 Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells. Stem Cells 28:1435-1445.
36. Yin J, Gao Z, He Q, Zhou D, Guo Z, Ye J 2009 Role of hypoxia in obesity-induced disorders of glucose and lipid metabolism in adipose tissue. Am J Physiol Endocrinol Metab 296:E333-E342.
37. Tajima R, Kawaguchi N, Horino Y, Takahashi Y, Toriyama K, Inou K, Torii S, Kitagawa Y 2001 Hypoxic enhancement of type IV collagen secretion accelerates adipose conversion of 3T3-L1 fibroblasts. Biochim Biophys Acta 1540:179-187.
38. Hosogai N, Fukuhara A, Oshima K, Miyata Y, Tanaka S, Segawa K, Furukawa S, Tochino Y, Komuro R, Matsuda M, Shimomura I 2007 Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 56:901-911.
39. Tisdale MJ 2002 Cachexia in cancer patients. Nat Rev Cancer 2:862-871.
40. Simha V, Garg A 2006 Lipodystrophy: lessons in lipid and energy metabolism. Curr Opin Lipidol 17:162-169.
41. Bing C, Russell S, Becket E, Pope M, Tisdale MJ, Trayhurn P, Jenkins JR 2006 Adipose atrophy in cancer cachexia: morphologic and molecular analysis of adipose tissue in tumour-bearing mice. Br J Cancer 95:1028-1037.
42. DahlmanI, Mejhert N, Linder K, Agustsson T, Mutch DM, Kulyte A, Isaksson B, Permert J, Petrovic N, Nedergaard J, Sjölin E, Brodin D, Clement K, Dahlman-Wright K, Rydén M, Arner P 2010 Adipose tissue pathways involved in weight loss of cancer cachexia. Br J Cancer 102:1541-1548.
43. Coss CC, Bohl CE, Dalton JT 2011 Cancer cachexia therapy: a key weapon in the fight against cancer. Curr Opin Clin Nutr Metab Care 14:268-273.
44. Kammoun HL, Hainault I, Ferré P, Foufelle F 2009 Nutritional related liver disease: targeting the endoplasmic reticulum stress. Curr Opin Clin Nutr Metab Care 12:575-582.
45. Regazzetti C, Peraldi P, Grémeaux T, Najem-Lendom R, Ben-Sahra I, Cormont M, Bost F, Le Marchand-Brustel Y, Tanti JF, Giorgetti-Peraldi S 2009 Hypoxia decreases insulin signaling pathways in adipocytes. Diabetes 58:95-103.
46. Elsharkawy AM, Mann DA 2007 Nuclear factor-κB and the hepatic inflammation-fibrosis-cancer axis. Hepatology 46:590-597.
47. Khan T, Muise ES, Iyengar P, Wang ZV, Chandalia M, Abate N, Zhang BB, Bonaldo P, Chua S, Scherer PE 2009 Metabolic dysregulation and adipose tissue fibrosis: role of collagen VI. Mol Cell Biol 29:1575-1591.
48. Li Q, Hata A, Kosugi C, Kataoka N, Funaki M 2010 The density of extracellular matrix proteins regulates inflammation and insulin signaling in adipocytes. FEBS Lett 584: 4145-4150.
49. Huang G, Ge G, Wang D, Gopalakrishnan B, Butz DH, Colman RJ, Nagy A, Greenspan DS 2011 α3(V) Collagen is critical for glucose homeostasis in mice due to effects in pancreatic islets and peripheral tissues. J Clin Invest 121: 769-783.
50. Zhou S, Lechpammer S, Greenberger JS, Glowacki J 2005 Hypoxia inhibition of adipocytogenesis in human bone marrow stromal cells requires transforming growth factor-β/Smad3 signaling. J Biol Chem 280:22688-22696.
51. Spencer M, Yao-Borengasser A, Unal R, Rasouli N, Gurley CM, Zhu B, Peterson CA, Kern PA 2010 Adipose tissue macrophages in insulin-resistant subjects are associated with collagen VI and fibrosis and demonstrate alternative activation. Am J Physiol Endocrinol Metab 299:E1016-E1027.
52. Halberg N, Wernstedt-Asterholm I, Scherer PE 2008 The adipocyte as an endocrine cell. Endocrinol Metab Clin North Am 37:753-768, x-xi.
53. Taleb S, Cancello R, Clément K, Lacasa D 2006 Cathepsin s promotes human preadipocyte differentiation: possible involvement of fibronectin degradation. Endocrinology 147:4950-4959.
54. Maquoi E, Munaut C, Colige A, Collen D, Lijnen HR 2002 Modulation of adipose tissue expression of murine matrix metalloproteinases and their tissue inhibitors with obesity. Diabetes 51:1093-1101.
55. Chavey C, Mari B, Monthouel MN, Bonnafous S, Anglard P, Van Obberghen E, Tartare-Deckert S 2003 Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation. J Biol Chem 278:11888-11896.
56. Boyd NF, Rommens JM, Vogt K, Lee V, Hopper JL, Yaffe MJ, Paterson AD 2005 Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol 6:798-808.
57. Van den Eynden GG, Colpaert CG, Couvelard A, Pezzella F, Dirix LY, Vermeulen PB, Van Marck EA, Hasebe T 2007 A fibrotic focus is a prognostic factor and a surrogate marker for hypoxia and (lymph) angiogenesis in breast cancer: review of the literature and proposal on the criteria of evaluation. Histopathology 51:440-451.
58. Kaminska B, Wesolowska A, Danilkiewicz M 2005 TGFβ signalling and its role in tumour pathogenesis. Acta Biochim Pol 52:329-337.
59. Radisky DC, Kenny PA, Bissell MJ 2007 Fibrosis and cancer: do myofibroblasts come also from epithelial cells via EMT? J Cell Biochem 101:830-839.
60. Andarawewa KL, Motrescu ER, Chenard MP, Gansmuller A, Stoll I, Tomasetto C, Rio MC 2005 Stromelysin-3 is a potent negative regulator of adipogenesis participating to cancer cell-adipocyte interaction/crosstalk at the tumor invasive front. Cancer Res 65:10862-10871.
61. Cao Y 2007 Angiogenesis modulates adipogenesis and obesity. J Clin Invest 117:2362-2368.
62. Ye J, Gao Z, Yin J, He Q 2007 Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol Endocrinol Metab 293:E1118-E1128.
63. Wood IS, de Heredia FP, Wang B, Trayhurn P 2009 Cellular hypoxia and adipose tissue dysfunction in obesity. Proc Nutr Soc 68:370-377.
64. Bråkenhielm E, Cao R, Gao B, Angelin B, Cannon B, Parini P, Cao Y 2004 Angiogenesis inhibitor, TNP-470, prevents diet-induced and genetic obesity in mice. Circ Res 94: 1579-1588.
65. Tilg H, Moschen AR 2006 Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6:772-783.
66. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE 2001 The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7:947-953.
67. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, KadowakiT 2003 Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762-769.
68. Hug C, Wang J, Ahmad NS, Bogan JS, Tsao TS, Lodish HF 2004 T-cadherin is a receptor for hexameric and highmolecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci USA 101:10308-10313.
69. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, Wagner JA, Wu M, Knopps A, Xiang AH, Utzschneider KM, Kahn SE, Olefsky JM, Buchanan TA, Scherer PE 2004 Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedionemediated improvement in insulin sensitivity. J Biol Chem 279:12152-12162.
70. Kelesidis I, Kelesidis T, Mantzoros CS 2006 Adiponectin and cancer: a systematic review. Br J Cancer 94:1221-1225.
71. Spyridopoulos TN, Petridou ET, Skalkidou A, Dessypris N, Chrousos GP, Mantzoros CS 2007 Low adiponectin levels are associated with renal cell carcinoma: a casecontrol study. Int J Cancer 120:1573-1578.
72. Yoneda K, Tomimoto A, Endo H, Iida H, Sugiyama M, Takahashi H, Mawatari H, Nozaki Y, Fujita K, Yoneda M, Inamori M, Nakajima N, Wada K, Nagashima Y, Nakagama H, Uozaki H, Fukayama M, Nakajima A 2008 Expression of adiponectin receptors, AdipoR1 and AdipoR2, in normal colon epithelium and colon cancer tissue. Oncol Rep 20:479-483.
73. Petridou ET, Mitsiades N, Gialamas S, Angelopoulos M, Skalkidou A, Dessypris N, Hsi A, Lazaris N, Polyzos A, Syrigos C, Brennan AM, Tseleni-Balafouta S, Mantzoros CS 2007 Circulating adiponectin levels and expression of adiponectin receptors in relation to lung cancer: two casecontrol studies. Oncology 73:261-269.
74. Takahata C, Miyoshi Y, Irahara N, Taguchi T, Tamaki Y, Noguchi S 2007 Demonstration of adiponectin receptors 1 and 2mRNAexpression inhumanbreast cancer cells. Cancer Lett 250:229-236.
75. Takemura Y, Osuga Y, Yamauchi T, Kobayashi M, Harada M, Hirata T, Morimoto C, Hirota Y, Yoshino O, Koga K, Yano T, Kadowaki T, Taketani Y 2006 Expression of adiponectin receptors and its possible implication in the human endometrium. Endocrinology 147:3203-3210.
76. Dalamaga M, Migdalis I, Fargnoli JL, Papadavid E, Bloom E, Mitsiades N, Karmaniolas K, Pelecanos N, Tseleni-Balafouta S, Dionyssiou-Asteriou A, Mantzoros CS 2009 Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case-control study. Cancer Causes Control 20:625-633.
77. Hebbard LW, Garlatti M, Young LJ, Cardiff RD, Oshima RG, RanschtB 2008 T-cadherin supports angiogenesis and adiponectin association with the vasculature in a mouse mammary tumor model. Cancer Res 68:1407-1416.
78. Kim KY, Baek A, Hwang JE, Choi YA, Jeong J, Lee MS, Cho DH, Lim JS, Kim KI, Yang Y 2009 Adiponectinactivated AMPK stimulates dephosphorylation of AKT through protein phosphatase 2A activation. Cancer Res 69:4018-4026.
79. Fujisawa T, Endo H, Tomimoto A, Sugiyama M, Takahashi H, Saito S, Inamori M, Nakajima N, Watanabe M, Kubota N, Yamauchi T, Kadowaki T, Wada K, Nakagama H, Nakajima A 2008 Adiponectin suppresses colorectal carcinogenesis under the high-fat diet condition. Gut 57: 1531-1538.
80. Rubenstein JH, Kao JY, Madanick RD, Zhang M, Wang M, Spacek MB, Donovan JL, Bright SD, Shaheen NJ 2009 Association of adiponectin multimers with Barrett's oesophagus. Gut 58:1583-1589.
81. Landskroner-Eiger S, Qian B, Muise ES, Nawrocki AR, Berger JP, Fine EJ, Koba W, Deng Y, Pollard JW, Scherer PE 2009 Proangiogenic contribution of adiponectin toward mammary tumor growth in vivo. Clin Cancer Res 15:3265-3276.
82. Denzel MS, Hebbard LW, Shostak G, Shapiro L, Cardiff RD, Ranscht B 2009 Adiponectin deficiency limits tumor vascularization in the MMTV-PyV-mT mouse model of mammary cancer. Clin Cancer Res 15:3256-3264.
83. Holland WL, Miller RA, Wang ZV, Sun K, Barth BM, Bui HH, Davis KE, Bikman BT, Halberg N, Rutkowski JM, Wade MR, Tenorio VM, Kuo MS, Brozinick JT, Zhang BB, Birnbaum MJ, Summers SA, Scherer PE 2011 Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med 17:55-63.
84. Reynolds CP, Maurer BJ, Kolesnick RN 2004 Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett 206:169-180.
85. Friedman JM, Halaas JL 1998 Leptin and the regulation of body weight in mammals. Nature 395:763-770.
86. Muoio DM, Lynis Dohm G 2002 Peripheral metabolic actions of leptin. Best Pract Res Clin Endocrinol Metab 16: 653-666.
87. Howard JM, Pidgeon GP, Reynolds JV 2010 Leptin and gastro-intestinal malignancies. Obes Rev 11:863-874.
88. Ishikawa M, Kitayama J, Nagawa H 2004 Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin Cancer Res 10:4325-4331.
89. Truett GE, Bahary N, Friedman JM, Leibel RL 1991 Rat obesity gene fatty (fa) maps to chromosome 5: evidence for homology with the mouse gene diabetes (db). Proc Natl Acad Sci USA 88:7806-7809.
90. Cleary MP, Juneja SC, Phillips FC, Hu X, Grande JP, Maihle NJ 2004 Leptin receptor-deficient MMTV-TGF-α/Lepr(db)Lepr(db) female mice do not develop oncogeneinduced mammary tumors. Exp BiolMed (Maywood) 229: 182-193.
91. Cleary MP, Phillips FC, Getzin SC, Jacobson TL, Jacobson MK, Christensen TA, Juneja SC, Grande JP, Maihle NJ 2003 Genetically obese MMTV-TGF-α/Lep(ob)Lep(ob) female mice do not develop mammary tumors. Breast Cancer Res Treat 77:205-215.
92. Hakkak R, Holley AW, Macleod SL, Simpson PM, Fuchs GJ, Jo CH, Kieber-Emmons T, Korourian S 2005 Obesity promotes 7,12-dimethylbenz(a)anthracene-induced mammary tumor development in female zucker rats. Breast Cancer Res 7:R627-633.
93. de Luca C, Kowalski TJ, Zhang Y, Elmquist JK, Lee C, Kilimann MW, Ludwig T, Liu SM, Chua Jr SC 2005 Complete rescue of obesity, diabetes, and infertility in db/db mice by neuron-specific LEPR-B transgenes. J Clin Invest 115:3484-3493.
94. Park J, Kusminski CM, Chua SC, Scherer PE 2010 Leptin receptor signaling supports cancer cell metabolism through suppression of mitochondrial respiration in vivo. Am J Pathol 177:3133-3144.
95. Cao L, Liu X, Lin EJ, Wang C, Choi EY, Riban V, Lin B, During MJ 2010 Environmental and genetic activation of a brain-adipocyte BDNF/leptin axis causes cancer remission and inhibition. Cell 142:52-64.
96. Pollak M 2008 Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8:915-928.
97. Renehan AG, Frystyk J, Flyvbjerg A 2006 Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab 17:328-336.
98. Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Hinshelwood MM, Graham-Lorence S, Amarneh B, Ito Y, Fisher CR, Michael MD, Mendelson CR, Bulun SE 1994 Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 15:342-355.
99. Simpson ER, Misso M, Hewitt KN, Hill RA, Boon WC, Jones ME, Kovacic A, Zhou J, Clyne CD 2005 Estrogen- the good, the bad, and the unexpected. Endocr Rev 26: 322-330.
100. Johnston SR, Dowsett M 2003 Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat Rev Cancer 3:821-831.
101. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P 2003 Overview of the main outcomes in breast-cancer prevention trials. Lancet 361:296-300.
102. Holland WL, Summers SA 2008 Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr Rev 29: 381-402.
103. Scherer PE 2006 Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 55:1537-1545.
104. Wellen KE, Hotamisligil GS 2003 Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 112:1785-1788.
105. Rocha VZ, Libby P 2009 Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol 6:399-409.
106. Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E, Wang S, Fortier M, Greenberg AS, Obin MS 2005 Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 46:2347-2355.
107. Murano I, Barbatelli G, Parisani V, Latini C, Muzzonigro G, Castellucci M, Cinti S 2008 Dead adipocytes, detected as crown-like structures, are prevalent in visceral fat depots of genetically obese mice. J Lipid Res 49:1562-1568.
108. Alkhouri N, Gornicka A, Berk MP, Thapaliya S, Dixon LJ, Kashyap S, Schauer PR, Feldstein AE 2010 Adipocyte apoptosis, a link between obesity, insulin resistance, and hepatic steatosis. J Biol Chem 285:3428-3438.
109. Nishimura S, Manabe I, Nagasaki M, Eto K, Yamashita H, Ohsugi M, Otsu M, Hara K, Ueki K, Sugiura S, Yoshimura K, Kadowaki T, Nagai R 2009 CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med 15:914-920.
110. Winer S, Chan Y, Paltser G, Truong D, Tsui H, Bahrami J, Dorfman R, Wang Y, Zielenski J, Mastronardi F, Maezawa Y, Drucker DJ, Engleman E, Winer D, Dosch HM 2009 Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med 15:921-929.
111. Feuerer M, Herrero L, Cipolletta D, Naaz A, Wong J, Nayer A, Lee J, Goldfine AB, Benoist C, Shoelson S, Mathis D 2009 Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med 15:930-939.
112. Markiewski MM, Lambris JD 2009 Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol 30:286-292.
113. Bui JD, Schreiber RD 2007 Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr Opin Immunol 19:203-208.
114. Pollard JW 2004 Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4:71-78.
115. Coussens LM, Werb Z 2002 Inflammation and cancer. Nature 420:860-867.
116. Mantovani A, Allavena P, Sica A, Balkwill F 2008 Cancerrelated inflammation. Nature 454:436-444.
117. Gupta RA, Dubois RN 2001 Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1:11-21.
118. Ulrich CM, Bigler J, Potter JD 2006 Non-steroidal antiinflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 6:130-140.
119. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE 2001 Reversal of obesity- and dietinduced insulin resistance with salicylates or targeted disruption of Ikkβ. Science 293:1673-1677.
120. Blobe GC, Obeid LM, Hannun YA 1994 Regulation of protein kinase C and role in cancer biology. Cancer Metastasis Rev 13:411-431.
121. Schütze S, Machleidt T, Krönke M 1994 The role of diacylglycerol and ceramide in tumor necrosis factor and interleukin-1 signal transduction. J Leukoc Biol 56:533-541.
122. Holland WL, Bikman BT, Wang LP, Yuguang G, Sargent KM, Bulchand S, Knotts TA, Shui G, Clegg DJ, WenkMR, Pagliassotti MJ, Scherer PE, Summers SA 2011 Lipidinduced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice. J Clin Invest 121:1858-1870.
123. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR 1999 Multilineage potential of adult human mesenchymal stem cells. Science 284:143-147.
124. Wassermann F 1926 The fat organs of man: development, structure, and systematic place of the so-called adipose tissue. Z Zellforsch Mikroskop Anat Abt Histochem 3:325.
125. Rosen ED, Spiegelman BM 2000 Molecular regulation of adipogenesis. Annu Rev Cell Dev Biol 16:145-171.
126. Vernochet C, Milstone DS, Iehlé C, Belmonte N, Phillips B, Wdziekonski B, Villageois P, Amri EZ, O'Donnell PE, Mortensen RM, Ailhaud G, Dani C 2002 PPARγ-dependent and PPARγ-independent effects on the development of adipose cells from embryonic stem cells. FEBS Lett 510: 94-98.
127. Sato M, Yajima Y, Kawashima S, Tanaka K, Kagechika H 2001 Synergistic potentiation of thiazolidinedioneinduced ST 13 preadipocyte differentiation by RAR synergists. Biochem Biophys Res Commun 280:646-651.
128. Kim JY, van de Wall E, Laplante M, Azzara A, Trujillo ME, Hofmann SM, Schraw T, Durand JL, Li H, Li G, Jelicks LA, Mehler MF, Hui DY, Deshaies Y, Shulman GI, Schwartz GJ, Scherer PE 2007 Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 117:2621-2637.
129. Rubin GL, Zhao Y, Kalus AM, Simpson ER 2000 Peroxisome proliferator-activated receptor γ ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res 60: 1604-1608.
130. Hudson AG, Gierach GL, Modugno F, Simpson J, Wilson JW, Evans RW, Vogel VG, Weissfeld JL 2008 Nonsteroidal anti-inflammatory drug use and serum total estradiol in postmenopausal women. Cancer Epidemiol Biomarkers Prev 17:680-687.
131. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T 2002 Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131-2139.
132. Geisler J, Haynes B, Anker G, Dowsett M, Lønning PE 2002 Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20:751-757.
133. Smith IE 2003 Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy. J Steroid Biochem Mol Biol 86:289-293.
134. Mouridsen H, Gershanovich M, Sun Y, Pérez-Carrión R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jänicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Lassus M, Verbeek JA, Staffler B, Chaudri-Ross HA, Dugan M 2001 Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19:2596-2606.
135. Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thürlimann B, von Euler M, Sahmoud T, Webster A, SteinbergM 2001 Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92:2247-2258.
136. Purohit A, Newman SP, Reed MJ 2002 The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer. Breast Cancer Res 4:65-69.
137. Brown KA, Simpson ER 2010 Obesity and breast cancer: progress to understanding the relationship. Cancer Res 70: 4-7.
138. Park SY, Lee JH, Kim KY, Kim EK, Yun SJ, Kim CD, Lee WS, Hong KW 2008 Cilostazol increases 3T3-L1 preadipocyte differentiation with improved glucose uptake associated with activation of peroxisome proliferatoractivated receptor-γ transcription. Atherosclerosis 201: 258-265.
139. Brown KA, Hunger NI, Docanto M, Simpson ER 2010 Metformin inhibits aromatase expression in human breastadipose stromal cells via stimulation of AMP-activated protein kinase. Breast Cancer Res Treat 123:591-596.
140. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J 1994 Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331:1188-1193.
141. Rohatagi S, Carrothers TJ, Jin J, Jusko WJ, Khariton T, Walker J, Truitt K, Salazar DE 2008 Model-based development of a PPARγ agonist, rivoglitazone, to aid dose selection and optimize clinical trial designs. J Clin Pharmacol 48:1420-1429.
142. Chen X, Osborne MC, Rybczynski PJ, Zeck R, Yang M, Xu J, Zhou L, Cryan E, Tang Y, Demarest KT 2005 Pharmacological profile of a novel, non-TZD PPAR_ agonist. Diabetes Obes Metab 7:536-546.
143. Kim J, Han DC, Kim JM, Lee SY, Kim SJ, Woo JR, Lee JW, Jung SK, Yoon KS, Cheon HG, Kim SS, Hong SH, Kwon BM 2009 PPAR γ partial agonist, KR-62776, inhibits adipocyte differentiation via activation of ERK. Cell Mol Life Sci 66:1766-1781.
144. Wang C, Pattabiraman N, Zhou JN, Fu M, Sakamaki T, Albanese C, Li Z, Wu K, Hulit J, Neumeister P, Novikoff PM, Brownlee M, Scherer PE, Jones JG, Whitney KD, Donehower LA, Harris EL, Rohan T, Johns DC, Pestell RG 2003 Cyclin D1 repression of peroxisome proliferatoractivated receptor γ expression and transactivation. Mol Cell Biol 23:6159-6173.
145. Sharma C, Pradeep A, Wong L, Rana A, Rana B 2004 Peroxisome proliferator-activated receptor γ activation can regulate β-catenin levels via a proteasome-mediated and adenomatous polyposis coli-independent pathway. J Biol Chem 279:35583-35594.
146. Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, Winer EP 2003 Use of the peroxisome proliferatoractivated receptor (PPAR) γ ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat 79:391-397.
147. Kulke MH, Demetri GD, Sharpless NE, Ryan DP, Shivdasani R, Clark JS, Spiegelman BM, Kim H, Mayer RJ, Fuchs CS 2002 A phase II study of troglitazone, an activator of the PPARγ receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J 8:395-399.
148. Smith MR, Manola J, Kaufman DS, George D, Oh WK, Mueller E, Slovin S, Spiegelman B, Small E, Kantoff PW 2004 Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer 101:1569-1574.
149. GirnunGD, Naseri E, Vafai SB, QuL, Szwaya JD, Bronson R, Alberta JA, Spiegelman BM 2007 Synergy between PPARγ ligands and platinum-based drugs in cancer. Cancer Cell 11:395-406.
150. Holland W, Morrison T, Chang Y, Wiernsperger N, Stith BJ 2004 Metformin (glucophage) inhibits tyrosine phosphatase activity to stimulate the insulin receptor tyrosine kinase. Biochem Pharmacol 67:2081-2091.
151. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M, Cantley LC 2005 The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310:1642-1246.
152. Bulcão C, Giuffrida FM, Ribeiro-Filho FF, Ferreira SR 2007 Are the beneficial cardiovascular effects of simvastatin and metformin also associated with a hormone-dependent mechanism improving insulin sensitivity? Braz J Med Biol Res 40:229-235.
153. Jakubowska J, Bohdanowicz-Pawlak A, Milewicz A, Szymczak J, Bednarek-Tupikowska G, Demissie M 2008 Plasma cytokines in obese women with polycystic ovary syndrome, before and after metformin treatment. Gynecol Endocrinol 24:378-384.
154. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL 2009 Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 137:482-488.
155. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y, Bost F 2008 The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27:3576-3586.
156. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN, Gonzalez-Angulo AM 2009 Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer [see comment]. J Clin Oncol 27:3297-3302.
157. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N 2007 Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67:10804-10812.
158. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M 2006 Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66:10269-10273.
159. MuellerWM, Stanhope KL, Gregoire F, Evans JL, Havel PJ 2000 Effects of metformin and vanadium on leptin secretion from cultured rat adipocytes. Obes Res 8:530-539.
160. He G, Pedersen SB, Bruun JM, Lihn AS, Richelsen B 2003 Metformin, but not thiazolidinediones, inhibits plasminogen activator inhibitor-1 production in human adipose tissue in vitro. Horm Metab Res 35:18-23.
161. Jacobs DB, Hayes GR, Truglia JA, Lockwood DH 1986 Effects of metformin on insulin receptor tyrosine kinase activity in rat adipocytes. Diabetologia 29:798-801.
162. Matthaei S, GretenH 1991 Evidence that metformin ameliorates cellular insulin-resistance by potentiating insulininduced translocation of glucose transporters to the plasma membrane. Diabete Metab 17:150-158.
163. Daval M, Foufelle F, Ferré P 2006 Functions of AMPactivated protein kinase in adipose tissue. J Physiol 574: 55-62.
164. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T 2002 Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288-1295.
165. Towler MC, Hardie DG 2007 AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 100:328-341.
166. Ren T, He J, Jiang H, Zu L, Pu S, Guo X, Xu G 2006 Metformin reduces lipolysis in primary rat adipocytes stimulated by tumor necrosis factor-α or isoproterenol. J Mol Endocrinol 37:175-183.
167. Saxena NK, Sharma D, Ding X, Lin S, Marra F, Merlin D, Anania FA 2007 Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptinmediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res 67:2497-2507.
168. Sharma D, Wang J, Fu PP, Sharma S, Nagalingam A, Mells J, HandyJ, Page AJ, CohenC, Anania FA, SaxenaNK 2010 Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology 52:1713-1722.
169. Somasundar P, Yu AK, Vona-Davis L, McFadden DW 2003 Differential effects of leptin on cancer in vitro. J Surg Res 113:50-55.
170. Ogunwobi O, Mutungi G, Beales IL 2006 Leptin stimulates proliferation and inhibits apoptosis in Barrett's esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2-mediated transactivation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation. Endocrinology 147:4505-4516.
171. Konturek PC, Burnat G, Rau T, Hahn EG, Konturek S 2008 Effect of adiponectin and ghrelin on apoptosis of Barrett adenocarcinoma cell line. Dig Dis Sci 53:597-605.
172. Rubenstein JH, Dahlkemper A, Kao JY, Zhang M, Morgenstern H, McMahon L, Inadomi JM 2008 A pilot study of the association of low plasma adiponectin and Barrett's esophagus. Am J Gastroenterol 103:1358-1364.
173. Ratke J, Entschladen F, Niggemann B, Zänker KS, Lang K 2010 Leptin stimulates the migration of colon carcinoma cells by multiple signaling pathways. Endocr Relat Cancer 17:179-189.
174. Jaffe T, Schwartz B 2008 Leptin promotes motility and invasiveness in human colon cancer cells by activating multiple signal-transduction pathways. Int J Cancer 123: 2543-2556.
175. Hardwick JC, Van Den Brink GR, Offerhaus GJ, Van Deventer SJ, Peppelenbosch MP 2001 Leptin is a growth factor for colonic epithelial cells. Gastroenterology 121: 79-90.
176. Jain SS, Bird RP 2010 Elevated expression of tumor necrosis factor-α signaling molecules in colonic tumors of Zucker obese (fa/fa) rats. Int J Cancer 127:2042-2050.
177. Fenton JI, Birmingham JM, Hursting SD, Hord NG 2008 Adiponectin blocks multiple signaling cascades associated with leptin-induced cell proliferation in Apc Min/+ colon epithelial cells. Int J Cancer 122:2437-2445.
178. Kim AY, Lee YS, Kim KH, Lee JH, Lee HK, Jang SH, Kim SE, Lee GY, Lee JW, Jung SA, Chung HY, Jeong S, Kim JB 2010 Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2-mediated AMPK activation. Mol Endocrinol 24:1441-1452.
179. Horiguchi A, Sumitomo M, Asakuma J, Asano T, Zheng R, Asano T, Nanus DM, Hayakawa M 2006 Leptin promotes invasiveness of murine renal cancer cells via extracellular signal-regulated kinases and rho dependent pathway. J Urol 176:1636-1641.
180. Attoub S, Noe V, Pirola L, Bruyneel E, Chastre E, Mareel M, Wymann MP, Gespach C 2000 Leptin promotes invasiveness of kidney and colonic epithelial cells via phosphoinositide 3-kinase-, rho-, and rac-dependent signaling pathways. FASEB J 14:2329-2338.
181. Pinthus JH, Kleinmann N, Tisdale B, Chatterjee S, Lu JP, Gillis A, Hamlet T, Singh G, Farrokhyar F, KapoorA 2008 Lower plasma adiponectin levels are associated with larger tumor size and metastasis in clear-cell carcinoma of the kidney. Eur Urol 54:866-873.
182. Onuma M, Bub JD, Rummel TL, Iwamoto Y 2003 Prostate cancer cell-adipocyte interaction: leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase. J Biol Chem 278: 42660-42667.
183. Park HY, Kwon HM, Lim HJ, Hong BK, Lee JY, Park BE, Jang Y, Cho SY, Kim HS 2001 Potential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro. Exp Mol Med 33:95-102.
184. Bub JD, Miyazaki T, Iwamoto Y 2006 Adiponectin as a growth inhibitor in prostate cancer cells. Biochem Biophys Res Commun 340:1158-1166.
185. Zhang T, He J, Xu C, Zu L, Jiang H, Pu S, Guo X, Xu G 2009 Mechanisms of metformin inhibiting lipolytic response to isoproterenol in primary rat adipocytes. J Mol Endocrinol 42:57-66.
186. Sharma D, Saxena NK, Vertino PM, Anania FA 2006 Leptin promotes the proliferative response and invasiveness in human endometrial cancer cells by activating multiple signal-transduction pathways. Endocr Relat Cancer 13:629-640.
187. Yin N, Wang D, Zhang H, Yi X, Sun X, Shi B, Wu H, Wu G, Wang X, Shang Y 2004 Molecular mechanisms involved in the growth stimulation of breast cancer cells by leptin. Cancer Res 64:5870-5875.
188. Lam JB, Chow KH, Xu A, Lam KS, Liu J, Wong NS, Moon RT, Shepherd PR, Cooper GJ, Wang Y 2009 Adiponectin haploinsufficiency promotes mammary tumor development inMMTV-PyVTmice by modulation of phosphatase and tensin homolog activities. PLoS One 4:e4968.
189. Wang Y, Lam JB, Lam KS, Liu J, Lam MC, Hoo RL, Wu D, Cooper GJ, Xu A 2006 Adiponectin modulates the glycogen synthase kinase-3β/β-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res 66:11462-11470.
190. Liu J, Lam JB, Chow KH, XuA, Lam KS, Moon RT, Wang Y 2008 Adiponectin stimulates Wnt inhibitory factor-1 expression through epigenetic regulations involving the transcription factor specificity protein 1. Carcinogenesis 29:2195-2202.
191. Gao J, Tian J, Lv Y, Shi F, Kong F, Shi H, Zhao L 2009 Leptin induces functional activation of cyclooxygenase-2 through JAK2/STAT3, MAPK/ERK, and PI3K/AKT pathways in human endometrial cancer cells. Cancer Sci 100: 389-395.
192. Catalano S, Giordano C, Rizza P, Gu G, Barone I, Bonofiglio D, Giordano F, Malivindi R, Gaccione D, Lanzino M, De Amicis F, Andó S 2009 Evidence that leptin through STAT and CREB signaling enhances cyclin D1 expression and promotes human endometrial cancer proliferation. J Cell Physiol 218:490-500.
193. Cong L, Gasser J, Zhao J, Yang B, Li F, Zhao AZ 2007 Human adiponectin inhibits cell growth and induces apoptosis in human endometrial carcinoma cells, HEC-1-A and RL95 2. Endocr Relat Cancer 14:713-720.
194. Keophiphath M, Achard V, Henegar C, Rouault C, Clé-ment K, Lacasa D 2009 Macrophage-secreted factors promote a profibrotic phenotype in human preadipocytes. Mol Endocrinol 23:11-24.
195. Hutley LJ, Newell FM, Joyner JM, Suchting SJ, Herington AC, Cameron DP, Prins JB 2003 Effects of rosiglitazone and linoleic acid on human preadipocyte differentiation. Eur J Clin Invest 33:574-581.
196. Sandouk T, Reda D, Hofmann C 1993 The antidiabetic agent pioglitazone increases expression of glucose transporters in 3T3-F442A cells by increasing messenger ribonucleic acid transcript stability. Endocrinology 133:352-359.
197. Kim YC, Gomez FE, Fox BG, Ntambi JM 2000 Differential regulation of the stearoyl-CoA desaturase genes by thiazolidinediones in 3T3-L1 adipocytes. J Lipid Res 41: 1310-1316.
198. Bouaboula M, Hilairet S, Marchand J, Fajas L, Le Fur G, Casellas P 2005 Anandamide induced PPARγ transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur J Pharmacol 517:174-181.
199. Janke J, Schupp M, Engeli S, Gorzelniak K, Boschmann M, Sauma L, Nystrom FH, Jordan J, Luft FC, Sharma AM 2006 Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-γ activation. J Hypertens 24:1809-1816.